- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07852637
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)
Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.
Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.
NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.
The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.
Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Yunjeong Song, RN
- Telefonnummer: 82-2-3410-2171
- E-post: yjung.song@sbri.co.kr
Studieorter
-
-
-
Busan, Sydkorea
- Dong-A University Hospital
-
Kontakt:
- Sung-Hyun Kim
-
Huvudutredare:
- Sung-Hyun Kim, MD, PhD
-
Goyang, Sydkorea
- Inje University Ilsan Paik Hospital
-
Kontakt:
- Min Sun Kim
-
Huvudutredare:
- Min Sun Kim
-
Gwangmyeong, Sydkorea
- Chung-Ang University Gwangmyeong Hospital
-
Kontakt:
- Eun Jeong Cho
-
Huvudutredare:
- Eun Jeong Cho
-
Hwasun, Sydkorea
- Chonnam National University Hwasun Hospital
-
Kontakt:
- Hyukjin Park
-
Huvudutredare:
- Hyukjin Park
-
Jeonju, Sydkorea
- Chonbuk National University Hospital
-
Kontakt:
- Ho-Young Yhim
-
Huvudutredare:
- Ho-Young Yhim, MD, PhD
-
Seoul, Sydkorea
- Kangbuk Samsung Hospital
-
Kontakt:
- Jiwon Kim
-
Huvudutredare:
- Jiwon Kim
-
Seoul, Sydkorea
- Korea University Anam Hospital
-
Kontakt:
- So Ree Kim
-
Huvudutredare:
- So Ree Kim
-
Seoul, Sydkorea
- Samsung Medical Center
-
Underutredare:
- Se-Hoon Lee, MD, PhD
-
Underutredare:
- Taek Kyu Park, MD, PhD
-
Kontakt:
- Yunjeong Song, RN
- E-post: yjung.song@sbri.co.kr
-
Huvudutredare:
- Eun Kyoung Kim, MD, PhD
-
Underutredare:
- David Hong, MD, PhD
-
Seoul, Sydkorea
- Seoul National University Hospital
-
Kontakt:
- Sang-Hoon Na, MD, PhD
-
Huvudutredare:
- Sang-Hoon Na, MD, PhD
-
Seoul, Sydkorea
- Konkuk University Medical Center
-
Kontakt:
- Ji-Won Hwang
-
Huvudutredare:
- Ji-Won Hwang
-
Seoul, Sydkorea
- Seoul St. Mary's Hospital
-
Kontakt:
- Mi-Hyang Jung
-
Huvudutredare:
- Mi-Hyang Jung, MD, PhD
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Sydkorea
- National Cancer Center
-
Kontakt:
- Mi-Hyang Kwak
-
Huvudutredare:
- Mi-Hyang Kwak
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Age ≥19 years.
-
Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:
- Proximal deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Both DVT and PE.
-
Any type of active cancer, defined by at least one of the following:
- Cancer diagnosed within the previous 6 months
- Locally advanced or metastatic cancer
- Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
- Cancer not in complete remission at the time of enrollment
- Ongoing cancer treatment or residual cancer.
-
Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.
Exclusion Criteria:
- Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
- Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
- Active major bleeding.
- An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
- Antiphospholipid syndrome.
- Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
- Pregnancy or breastfeeding.
- Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
- Thrombocytopenia with a platelet count <50,000/mm³.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Edoxaban-based Treatment
Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors. |
Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered. |
|
Aktiv komparator: Apixaban-based Treatment
Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol. |
Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Net Adverse Clinical Events (NACE)
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. |
From randomization until 1 year after enrollment of the last participant
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death. |
From randomization until 1 year after enrollment of the last participant
|
|
Recurrent Venous Thromboembolism
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism. |
From randomization until 1 year after enrollment of the last participant
|
|
Venous Thromboembolism-related Death
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee. |
From randomization until 1 year after enrollment of the last participant
|
|
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells. |
From randomization until 1 year after enrollment of the last participant
|
|
Clinically Relevant Non-major Bleeding
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy. |
From randomization until 1 year after enrollment of the last participant
|
|
Clinically Relevant Bleeding
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding. |
From randomization until 1 year after enrollment of the last participant
|
|
Broad Net Adverse Clinical Events
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding. |
From randomization until 1 year after enrollment of the last participant
|
|
All-cause Mortality
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Death due to any cause occurring during the study follow-up period. |
From randomization until 1 year after enrollment of the last participant
|
|
Permanent Discontinuation Due to Adverse Events
Tidsram: From randomization until 1 year after enrollment of the last participant
|
Permanent discontinuation of the assigned study drug due to any adverse event during follow-up. |
From randomization until 1 year after enrollment of the last participant
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Eun Kyoung Kim, Samsung Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026-07-044
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.
Tidsram för IPD-delning
Beginning after publication of the main study results; no predetermined end date.
Kriterier för IPD Sharing Access
Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .